# Association Between Specialist Distribution and Regional Variation in Plasmapheresis Use in Japan: A Population‐Level Cross‐Sectional Study

**Authors:** Ryuichi Yoshimura, Kosuke Matsui, Masahiro Egawa, Yasuko Ito, Kaori Yoshikane, Takafumi Ito

PMC · DOI: 10.1002/jca.70112 · Journal of Clinical Apheresis · 2026-03-15

## TL;DR

The study finds that plasmapheresis use in Japan varies greatly by region and is linked to the number of nephrologists in those areas.

## Contribution

This study is the first to show a significant association between nephrologist distribution and plasmapheresis use in Japan.

## Key findings

- Plasmapheresis use varied 6.5-fold across regions in Japan.
- Each additional nephrologist per 100,000 people was linked to a 1.11-fold increase in plasmapheresis use.
- Dialysis and apheresis specialists showed no significant association with plasmapheresis use.

## Abstract

Plasmapheresis is widely used in Japan; however, regional variation in its use and its association with specialist distribution remain unclear. We conducted a cross‐sectional study using the 9th National Database Open Data (fiscal year 2022) to assess regional variation in plasmapheresis use and examined its association with the distribution of nephrologists, dialysis specialists, and apheresis specialists. Plasmapheresis use was identified using the relevant receipt code, and age‐ and sex‐adjusted standardized claim ratios (SCRs) were calculated. Plasmapheresis use differed 6.5‐fold across regions, with SCRs ranging from 34.0 to 222.4. Multivariable‐adjusted negative binomial regression models showed that each additional board‐certified nephrologist per 100 000 population was associated with a 1.11‐fold increase in the SCR (β = 0.11; 95% confidence interval: 0.02–0.20; p = 0.022). No significant associations were observed for board‐certified dialysis or apheresis specialists. These findings indicate substantial regional disparities and suggest that nephrologist distribution may influence plasmapheresis utilization in Japan.

## Full-text entities

- **Diseases:** asthma (MESH:D001249), cancer (MESH:D009369), autoimmune (MESH:D001327), peripheral artery disease (MESH:D058729)
- **Chemicals:** benralizumab (MESH:C571386)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12989638/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12989638/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12989638/full.md

---
Source: https://tomesphere.com/paper/PMC12989638